Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.

ABSTRACT:

Background

COVID-19 is more severe in transplant recipients. Variants of concern have supplanted wild-type virus. In transplant recipients, data are limited on 2-dose or 3-dose vaccine immunogenicity against variant viruses.

Objective

To assess neutralizing antibody responses against SARS-CoV-2 variants in transplant recipients after 2 and 3 vaccine doses.

Design

Secondary analysis of a randomized, double-blind, controlled trial of a third dose of mRNA-1273 vaccine versus placebo. (ClinicalTrials.gov: NCT04885907).

Setting

Single-center transplant program.

Patients

Organ transplant recipients.

Intervention

Third dose of mRNA-1273 vaccine versus placebo.

Measurements

Sera were analyzed for neutralization against wild-type virus and the Alpha

SUBMITTER: Kumar D 

PROVIDER: S-EPMC8628360 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature